Scleroderma-like Fibrosing Disorders

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 199-220

  Boin, Francesco ^a   Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GADODIAMIDE; GADOLINIUM; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLIN G; PREDNISONE; PSORALEN; RAPAMYCIN; TACROLIMUS; THALIDOMIDE;

CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EOSINOPHILIC FASCIITIS; FIBROSIS; HUMAN; MEDICAL ASSESSMENT; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SCLEREDEMA; SCLERODERMA; SCLEROMYXEDEMA; SHULMAN SYNDROME; SKIN FIBROSIS; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; FASCIITIS; FIBROSIS; HUMANS; SCLERODERMA, DIFFUSE; SCLEROMYXEDEMA; SKIN;

EID: 40449111254     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.11.001     Document Type: Review

References (108)

1. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 9234 (2000) 1000-1001
2. Jan F., Segal J.M., Dyer J., et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143 5 (2003) 678-681
3. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001-2007. Available at: http://www.icnfdr.org. Accessed May 11, 2007.
4. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 5 (2001) 383-393
5. Ting W.W., Stone M.S., Madison K.C., et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 7 (2003) 903-906
6. Fazeli A., Lio P.A., and Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link?. Arch Dermatol 140 11 (2004) 1401
7. Swaminathan S., Ahmed I., McCarthy J.T., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 3 (2006) 234-235
8. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 9 (2006) 2359-2362
9. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 4 (2006) 1104-1108
10. Khurana A., Runge V.M., Narayanan M., et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42 2 (2007) 139-145
11. High W.A., Ayers R.A., Chandler J., et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 1 (2007) 21-26
12. Grobner T., and Prischl F.C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72 3 (2007) 260-264
13. Barnhart J.L., Kuhnert N., Bakan D.A., et al. Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn Reson Imaging 5 3 (1987) 221-231
14. Food and Drug Administration. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI). 2006. Available at: http://www.fda.gov/cder/drug/infopage/gcca/default.htm. Accessed December 28, 2007.
15. Quan T.E., Cowper S., Wu S.P., et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36 4 (2004) 598-606
16. Haroon Z.A., Amin K., Jiang X., et al. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163 3 (2003) 993-1000
17. Galan A., Cowper S.E., and Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18 6 (2006) 614-617
18. Richmond H., Zwerner J., Kim Y., et al. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 143 8 (2007) 1025-1030
19. Gilliet M., Cozzio A., Burg G., et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152 3 (2005) 531-536
20. Baron P.W., Cantos K., Hillebrand D.J., et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25 3 (2003) 204-209
21. Chung H.J., and Chung K.Y. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150 3 (2004) 596-597
22. Kafi R., Fisher G.J., Quan T., et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140 11 (2004) 1322-1324
23. Yerram P., Saab G., Karuparthi P.R., et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2 2 (2007) 258-263
24. Kay J. Imatinib mesylate treatment improves skin changes of nephrogenic systemic fibrosis. Arthritis Rheum 56 9 (2007) S64
25. Shulman L.E. Diffuse fasciitis with hypergamaglobulinemia and eosinophilia: a new syndrome?. J Rheumatol 1 Suppl 1 (1974) 46
26. Rodnan G.P., DiBartolomeo A.G., Medsger T.A., et al. Eosinophilic fasciitis: report of seven cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 18 4 (1975) 422
27. Lakhanpal S., Ginsburg W.W., Michet C.J., et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17 4 (1988) 221-231
28. Grisanti M.W., Moore T.L., Osborn T.G., et al. Eosinophilic fasciitis in children. Semin Arthritis Rheum 19 3 (1989) 151-157
29. Tabuenca J.M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2 8246 (1981) 567-568
30. Slutsker L., Hoesly F.C., Miller L., et al. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 264 2 (1990) 213-217
31. Toquet C., Hamidou M.A., Renaudin K., et al. In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 30 8 (2003) 1811-1815
32. Viallard J.F., Taupin J.L., Ranchin V., et al. Analysis of leukemia inhibitory factor, type 1, and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 28 1 (2001) 75-80
33. Dziadzio L., Kelly E.A., Panzer S.E., et al. Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol 90 4 (2003) 452-455
34. Kariyawasam H.H., and Robinson D.S. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 27 2 (2006) 117-127
35. Birkland T.P., Cheavens M.D., and Pincus S.H. Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts. Arch Dermatol Res 286 6 (1994) 312-318
36. Kahari V.M., Heino J., Niskanen L., et al. Eosinophilic fasciitis. Increased collagen production and type I procollagen messenger RNA levels in fibroblasts cultured from involved skin. Arch Dermatol 126 5 (1990) 613-617
37. Granter S.R., Barnhill R.L., Hewins M.E., et al. Identification of Borrelia burgdorferi in diffuse fasciitis with peripheral eosinophilia: borrelial fasciitis. JAMA 272 16 (1994) 1283-1285
38. Hashimoto Y., Takahashi H., Matsuo S., et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 192 2 (1996) 136-139
39. Anton E. Failure to demonstrate Borrelia burgdorferi-specific DNA in lesions of eosinophilic fasciitis. Histopathology 49 1 (2006) 88-90
40. Endo Y., Tamura A., Matsushima Y., et al. Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 26 9 (2007) 1445-1451
41. Bielsa I., and Ariza A. Deep morphea. Semin Cutan Med Surg 26 2 (2007) 90-95
42. Garcia V.P., de Quiros J.F., and Caminal L. Autoimmune hemolytic anemia associated with eosinophilic fasciitis. J Rheumatol 25 9 (1998) 1864-1865
43. Bachmeyer C., Monge M., Dhote R., et al. Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. Dermatology 199 3 (1999) 282
44. Junca J., Cuxart A., Tural C., et al. Eosinophilic fasciitis and non-Hodgkin lymphoma. Eur J Haematol 52 5 (1994) 304-306
45. Eklund K.K., Anttila P., and Leirisalo-Repo M. Eosinophilic fasciitis, myositis, and arthritis as early manifestations of peripheral T-cell lymphoma. Scand J Rheumatol 32 6 (2003) 376-377
46. Khanna D., Verity A., and Grossman J.M. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 61 12 (2002) 1111-1112
47. Moulton S.J., Kransdorf M.J., Ginsburg W.W., et al. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol 184 3 (2005) 975-978
48. Antic M., Lautenschlager S., and Itin P.H. Eosinophilic fasciitis 30 years after-what do we really know? Report of 11 patients and review of the literature. Dermatology 213 2 (2006) 93-101
49. Rongioletti F., and Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 44 2 (2001) 273-281
50. Dinneen A.M., and Dicken C.H. Scleromyxedema. J Am Acad Dermatol 33 1 (1995) 37-43
51. Pomann J.J., and Rudner E.J. Scleromyxedema revisited. Int J Dermatol 42 1 (2003) 31-35
52. Clark B.J., Mowat A., Fallowfield M.E., et al. Papular mucinosis: is the inflammatory cell infiltrate neoplastic? The presence of a monotypic plasma cell population demonstrated by in situ hybridization. Br J Dermatol 135 3 (1996) 467-470
53. Ferrarini M., Helfrich D.J., Walker E.R., et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 16 6 (1989) 837-841
54. Harper R.A., and Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 199 4328 (1978) 545-547
55. Lacy M.Q., Hogan W.J., Gertz M.A., et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 141 10 (2005) 1277-1282
56. Shergill B., Orteu C.H., McBride S.R., et al. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 153 3 (2005) 650-652
57. Berger J.R., Dobbs M.R., Terhune M.H., et al. The neurologic complications of scleromyxedema. Medicine (Baltimore) 80 5 (2001) 313-319
58. Nieves D.S., Bondi E.E., Wallmark J., et al. Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. Cutis 65 2 (2000) 89-92
59. Godby A., Bergstresser P.R., Chaker B., et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 38 2 (1998) 289-294
60. Webster G.F., Matsuoka L.Y., and Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 28 1 (1993) 105-108
61. Majeski C., Taher M., Grewal P., et al. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg 9 3 (2005) 99-104
62. Feldman P., Shapiro L., Pick A.I., et al. Scleromyxedema. A dramatic response to melphalan. Arch Dermatol 99 1 (1969) 51-56
63. Harris R.B., Perry H.O., Kyle R.A., et al. Treatment of scleromyxedema with melphalan. Arch Dermatol 115 3 (1979) 295-299
64. Helm F., and Helm T.N. Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema. Cutis 39 3 (1987) 219-223
65. Gabriel S.E., Perry H.O., Oleson G.B., et al. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 67 1 (1988) 58-65
66. Kuldeep C.M., Mittal A.K., Gupta L.K., et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol 71 1 (2005) 44-45
67. Rongioletti F., Hazini A., and Rebora A. Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol 144 6 (2001) 1283-1284
68. Saigoh S., Tashiro A., Fujita S., et al. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology 207 4 (2003) 410-411
69. Sansbury J.C., Cocuroccia B., Jorizzo J.L., et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 51 1 (2004) 126-131
70. Caradonna S., and Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 140 3 (2004) 277-280
71. Thyssen J.P., Zachariae C., and Menne T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 20 10 (2006) 1396-1397
72. Jacob S.E., Fien S., and Kerdel F.A. Scleromyxedema, a positive effect with thalidomide. Dermatology 213 2 (2006) 150-152
73. Amini-Adle M., Thieulent N., Dalle S., Blade J., et al. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 214 1 (2007) 58-60
74. Iranzo P., Lopez-Lerma I., Blade J., et al. Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol 21 1 (2007) 129-130
75. Donato M.L., Feasel A.M., Weber D.M., et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107 2 (2006) 463-466
76. Illa I., de la Torre C., Rojas-Garcia R., et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood 108 2 (2006) 773-774
77. Lister R.K., Jolles S., Whittaker S., et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43 2 (2000) 403-408
78. Righi A., Schiavon F., Jablonska S., et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 61 1 (2002) 59-61
79. Kulczycki A., Nelson M., Eisen A., et al. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149 6 (2003) 1276-1281
80. Wojas-Pelc A., Blaszczyk M., Glinska M., et al. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 19 4 (2005) 462-465
81. Greenberg L.M., Geppert C., Worthen H.G., et al. Scleredema adultorum in children. Report of three cases with histochemical study and review of world literature. Pediatrics 32 (1963) 1044-1054
82. Sattar M.A., Diab S., Sugathan T.N., et al. Scleroedema diabeticorum: a minor but often unrecognized complication of diabetes mellitus. Diabet Med 5 5 (1988) 465-468
83. Vijayasingam S.M., Thai A.C., and Chan H.L. Noninfective skin associations of diabetes mellitus. Ann Acad Med Singapore 17 4 (1988) 526-535
84. Cole G.W., Headley J., and Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 6 2 (1983) 189-192
85. Tate B.J., Kelly J.W., and Rotstein H. Scleredema of Buschke: a report of seven cases. Australas J Dermatol 37 3 (1996) 139-142
86. Tsunemi Y., Ihn H., Fujita H., et al. Square-shaped scleredema in the back: probably induced by mechanical stress. Int J Dermatol 44 9 (2005) 769-770
87. Ranganathan P. Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rheumatol 11 6 (2005) 319-322
88. Beers W.H., Ince A., and Moore T.L. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 35 6 (2006) 355-359
89. Kovary P.M., Vakilzadeh F., Macher E., et al. Monoclonal gammopathy in scleredema. Observations in three cases. Arch Dermatol 117 9 (1981) 536-539
90. Ratip S., Akin H., Ozdemirli M., et al. Scleredema of Buschke associated with Waldenstrom's macroglobulinaemia. Br J Dermatol 143 2 (2000) 450-452
91. Leung C.S., and Chong L.Y. Scleredema in Chinese patients: a local retrospective study and general review. Hong Kong Med J 4 1 (1998) 31-35
92. Ioannidou D.I., Krasagakis K., Stefanidou M.P., et al. Scleredema adultorum of Buschke presenting as periorbital edema: a diagnostic challenge. J Am Acad Dermatol 52 2 Suppl 1 (2005) 41-44
93. Ulmer A., Schaumburg-Lever G., Bauer J., et al. Scleredema adultorum Buschke. Case report and review of the literature. Hautarzt 49 1 (1998) 48-54
94. Wright R.A., and Bernie H. Scleredema adultorum of Buschke with upper esophageal involvement. Am J Gastroenterol 77 1 (1982) 9-11
95. Paz R.A., Badra R.E., Marti H.M., et al. Systemic Buschke's scleredema with cardiomyopathy, monoclonal IgG kappa gammopathy and amyloidosis. Case report with autopsy. Medicina (B Aires) 58 5 Pt 1 (1998) 501-503
96. Livieri C., Monafo V., Bozzola M., et al. Buschke's scleredema and carditis: a clinical case. Pediatr Med Chir 4 6 (1982) 695-697
97. Rho Y.W., Suhr K.B., Lee J.H., et al. A clinical observation of scleredema adultorum and its relationship to diabetes. J Dermatol 25 2 (1998) 103-107
98. Venencie P.Y., Powell F.C., Su W.P., et al. Scleredema: a review of thirty-three cases. J Am Acad Dermatol 11 1 (1984) 128-134
99. Breuckmann F., Appelhans C., Harati A., et al. Failure of low-dose methotrexate in the treatment of scleredema diabeticorum in seven cases. Dermatology 211 3 (2005) 299-301
100. Nakajima K., Iwagaki M., Ikeda M., et al. Two cases of diabetic scleredema that responded to PUVA therapy. J Dermatol 33 11 (2006) 820-822
101. Tuchinda C., Kerr H.A., Taylor C.R., et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 22 5 (2006) 247-253
102. Eberlein-Konig B., Vogel M., Katzer K., et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 19 2 (2005) 203-204
103. Grundmann-Kollmann M., Ochsendorf F., Zollner T.M., et al. Cream PUVA therapy for scleredema adultorum. Br J Dermatol 142 5 (2000) 1058-1059
104. Hager C.M., Sobhi H.A., Hunzelmann N., et al. Bath-PUVA therapy in three patients with scleredema adultorum. J Am Acad Dermatol 38 2 Pt 1 (1998) 240-242
105. Stables G.I., Taylor P.C., and Highet A.S. Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol 142 4 (2000) 781-783
106. Konemann S., Hesselmann S., Bolling T., et al. Radiotherapy of benign diseases-scleredema adultorum Buschke. Strahlenther Onkol 180 12 (2004) 811-814
107. Bowen A.R., Smith L., and Zone J.J. Scleredema adultorum of Buschke treated with radiation. Arch Dermatol 139 6 (2003) 780-784
108. Tobler M., Leavitt D.D., and Gibbs Jr. F.A. Dosimetric evaluation of a specialized radiotherapy treatment technique for scleredema. Med Dosim 25 4 (2000) 215-218